Evaluation of Wearable Digital Devices in a Phase I Clinical Trial

We assessed the performance of two US Food and Drug Administration (FDA) 510(k)‐cleared wearable digital devices and the operational feasibility of deploying them to augment data collection in a 10‐day residential phase I clinical trial. The Phillips Actiwatch Spectrum Pro (Actiwatch) was used to as...

Descripción completa

Detalles Bibliográficos
Autores principales: Izmailova, Elena S., McLean, Ian L., Bhatia, Gaurav, Hather, Greg, Cantor, Matthew, Merberg, David, Perakslis, Eric D., Benko, Christopher, Wagner, John A.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2019
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6510458/
https://www.ncbi.nlm.nih.gov/pubmed/30635980
http://dx.doi.org/10.1111/cts.12602

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6510458/
https://www.ncbi.nlm.nih.gov/pubmed/30635980
http://dx.doi.org/10.1111/cts.12602

Ejemplares similares